Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709358 | 0.90 | SIRT6 (0.56) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL22551116 | 0.82 | HPN (0.50) | MAPTALDH1A1LMNASCN2AMEN1 | |
| SCHEMBL14491992 | 0.78 | DDB1 (0.53) | MAPTALDH1A1POLBLMNACRBN | |
| SCHEMBL4471542 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1POLBLMNAMEN1 | |
| SCHEMBL3641871 | 0.77 | POLB (0.43) | ALDH1A1POLBLMNAMEN1KMT2A | |
| SCHEMBL29929946 | 0.77 | MEN1 (0.56) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL77999 | 0.77 | MEN1 (0.56) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL2300461 | 0.77 | ALDH1A1 (0.48) | SIRT6ADRB1MAPTALDH1A1POLB | |
| SCHEMBL8286230 | 0.76 | SMN1; SMN2 (0.54) | ADRB1MAPTALDH1A1POLBLMNA | |
| SCHEMBL1259982 | 0.76 | ALDH1A1 (0.46) | MAPTALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | SIRT6 3566/4885ADRB1 238/4885MAPT 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.